Adar Poonawalla, Serum Institute of India CEO (Dhiraj Singh/Bloomberg via Getty Images)

Green­Light li­cens­es mR­NA shin­gles vac­cine to Serum In­sti­tute fol­low­ing a $10M in­vest­ment

Green­Light Bio­sciences has come a long way from try­ing to shake up the pes­ti­cides mar­ket.

The Med­ford, MA biotech signed a deal Mon­day with the Serum In­sti­tute of In­dia to de­sign three mR­NA prod­ucts, in­clud­ing a shin­gles vac­cine, for de­vel­op­ment, man­u­fac­tur­ing and com­mer­cial­iza­tion in a num­ber of mar­kets around the world.

Green­Light will re­tain the rights to North Amer­i­ca, Eu­rope, Aus­tralia, New Zealand, Chi­na, Japan and South Ko­rea, while SII will get a tech trans­fer to work in Africa, Latin Amer­i­ca, the Mid­dle East and much of Asia. The deal pig­gy­backs off of a $10 mil­lion in­vest­ment made by Serum Life Sci­ences in No­vem­ber 2021.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.